Latest Administration News

Sayona Mining has updated its timetable for the merger with Piedmont Lithium, conditional placement, and share consolidation, aiming to simplify and speed up the process pending shareholder approval.

Lachlan Star Limited reports promising maiden drilling results at its Killaloe Gold Project in Western Australia and initiates copper-gold drilling at North Cobar, NSW, while securing permits for further Basin Creek exploration.

One Click Group Limited has outpaced its entire July 2024 revenue within the first 18 days of July 2025, defying a broader decline in tax lodgements and showcasing strong customer loyalty.

Paladin Energy reported a $18.4 million operating cash outflow in Q2 2025 but maintains a strong liquidity position with $89 million in cash and $139 million in total available funding.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Plenti Group has reported a third consecutive record quarter with $437 million in loan originations, driven by strong automotive and NAB partnership growth. The fintech lender also secured a key government contract and continues to deliver low credit losses.

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.

Nordic Resources has completed a major acquisition of three advanced gold projects in Finland, lifting its total gold equivalent resources to 1.23 million ounces. The company also secured A$3.5 million in institutional funding and appointed a seasoned mining executive as Chairman.

Polymetals Resources has updated its June 2025 quarterly cash flow report, confirming nearly two quarters of funding and ongoing revenue from concentrate sales. The company’s financing position remains stable amid planned equity issuance.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Austal Limited has acknowledged a delayed filing of a director's interest notice due to an administrative oversight, prompting ASX scrutiny and a commitment to tighten compliance processes.